AsianScientist (Jan. 13, 2014) – Mundipharma, a pain-management and drug-delivery company, has launched OxyNorm® injections, a product for post-operative pain, in China.
OxyNorm® injections are a drug treatment to manage post-operative pain following surgery that may require the use of strong opioids. OxyNorm® injections contain the active ingredient oxycodone, which is documented for its analgesic efficacy and fewer side effects such as nausea, vomiting, nightmares or hallucinations, and for its rapid onset of action while still remaining a long-standing opioid.
“There is a great unmet need in the treatment of pain in China and it is our responsibility as a company to harness innovation to provide patients with easier access to therapeutic strategies to improve the quality of their lives. In fact, more than 80 percent of patients are needlessly experiencing post-operative pain of acute pain with 71 percent of this being moderate-to-severe,” said Raman Singh, regional managing director of Mundipharma Asia.
——
Source: Mundipharma; Photo: Daniel Paquet/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
